Back to Journals » Drug Design, Development and Therapy » Volume 5

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

Total article views   Abstract views HTML views PDF downloads Totals
33,368 Dovepress* 16,179 707+ 5,583 16,886
PubMed Central* 26 16,456 5,148 16,482
Totals 16,205 17,163 10,731 33,368
*Since 23 November 2011
+Since July 2016

View citations on PubMed Central and Google Scholar